局部治疗后复发黑色素瘤辅助PD-1免疫治疗后采用BRAF/MEK抑制剂「二次辅助」治疗的疗效与安全性
回顾性多中心研究纳入73例BRAF突变黑色素瘤患者,其中61例接受「二次辅助」BRAF/MEK抑制剂治疗,12例未接受。中位随访26.1个月,二次辅助组无复发生存期改善(中位30.8 vs 4个月,HR 0.35;p=0.014),总生存无差异(p=0.59),但毒性明显,23%发生3级及以上毒性,38%因毒性永久停药。
要点
- 二次辅助BRAF/MEKi组中位RFS 30.8个月 vs 未接受组4个月(HR 0.35;p=0.014)。
- 总生存无差异(p=0.59),获益主要来自延迟早期复发。
- 23%发生3级及以上毒性,38%因毒性永久停药。
核心结论
- 这是首个评估辅助PD-1免疫治疗失败后黑色素瘤「二次辅助」靶向治疗结局的研究。
- 数据提示RFS短期改善,但以毒性为代价;需要替代策略及更多辅助治疗序贯数据来改善结局。
研究设计与样本
- 回顾性研究,从13个中心识别接受辅助PD-1免疫治疗后复发、接受确定性局部治疗、随后接受辅助BRAF/MEKi的BRAF突变黑色素瘤患者(二次辅助组)。
- 共纳入73例患者,其中61例接受「二次辅助」治疗,12例未接受(无二次辅助组)。
- 比较两组的人口学、疾病与治疗特征及结局数据。
主要发现
- 多数患者最初在PD-1治疗中复发(66%)。
- 两组特征无差异。
- 二次辅助组92%接受达拉非尼联合曲美替尼,中位治疗时长11.8个月(0.4,34.5)。
- 二次辅助组72%需要剂量调整,23%发生3级及以上毒性,38%因毒性永久停药。
- 中位随访26.1个月(1.9,56.3)后,二次辅助组较无二次辅助组RFS改善(中位30.8 vs 4个月,HR 0.35;p=0.014),主要驱动为延迟早期复发,总生存无差异(p=0.59)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-PD-1 antibodies and BRAK/MEK inhibitors (BRAF/MEKi) reduce the risk of recurrence for patients with resected stage III melanoma. BRAFV600-mutated (BRAFmut) melanoma patients who recur with isolated disease following adjuvant therapy may be suitable for 'second adjuvant' treatment after local therapy. We sought to examine the efficacy and safety of 'second adjuvant' BRAF/MEKi. PATIENTS AND METHODS: Patients with BRAFmut melanoma treated with adjuvant PD-1 based immunotherapy who recurred, underwent definitive local therapy and were then treated with adjuvant BRAF/MEKi were identified retrospectively from 13 centres (second adjuvant group). Demographics, disease and treatment characteristics and outcome data were examined. Outcomes were compared to BRAFmut patients who did not receive 'second adjuvant' therapy (no second adjuvant group). RESULTS: 73 patients were included; 61 who received 'second adjuvant' therapy and 12 who did not. Most initially recurred on PD-1 therapy (66%). There were no differences in characteristics between groups. 92% of second adjuvant group received dabrafenib and trametinib and median duration of therapy was 11.8 months (0.4, 34.5). 72% required dose adjustments, 23% had grade 3 + toxicity and 38% permanently discontinued drug due to toxicity. After median 26.1 months (1.9, 56.3) follow-up, recurrence-free survival (RFS) was improved in second adjuvant group versus no second adjuvant group (median 30.8 vs 4 months, HR 0.35; p = 0.014), largely driven by a delay in early recurrence, with no difference in overall survival (p = 0.59). CONCLUSION: This is the first study examining outcomes of 'second adjuvant' targeted therapy for melanoma, after failure of adjuvant PD-1 based immunotherapy. Data suggest a short-term improvement in RFS, but at the cost of toxicity. Alternative strategies and more data on sequencing adjuvant therapies are required to improve outcomes.
引用
- Taylor AM, McKeown J, Dimitriou F, et al. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy. Eur J Cancer. 2024. PMID: 38278009. doi:10.1016/j.ejca.2024.113561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。